Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinblastine + sirolimus
- Development stage
- Phase 1
- Lead developer
- SickKids
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of vinblastine, a vinca alkaloid that inhibits mitosis by binding to tubulin, and sirolimus (rapamycin), an mTOR inhibitor. This combination has been studied primarily for pediatric patients with recurrent or refractory solid tumors, including neuroblastoma and CNS tumors. The combination works through both anti-proliferative and anti-angiogenic mechanisms, showing synergistic effects in inhibiting tumor growth, inducing apoptosis, and reducing angiogenesis.
02
Targets
TUBB (Tubulin (alpha and beta subunits))Mechanistic target of rapamycin complex 1VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on vinblastine + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinblastine + sirolimus.